Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin-3 (SNX3) is a member of the sorting nexin protein family, characterized by containing only a single Phox homology (PX) domain and lacking additional structural motifs present in other family members[1][3]. SNX3 localizes predominantly to early endosomes by recognizing phosphatidylinositol 3-phosphate (PI3P) and plays a crucial role in endosomal membrane trafficking, including recruiting the retromer complex to segregate and sort cargo such as transmembrane receptors[1][3]. SNX3 is essential for both retromer-dependent trafficking to the trans-Golgi network and retromer-independent recycling via tubular endosomes[2]. Its interaction with endosomal membranes is regulated by phosphorylation at a conserved serine near the PI3P binding pocket, acting as a switch for membrane association[1]. Misregulation of SNX3 has been implicated in certain cancers, such as breast cancer, due to its potential influence on endocytic trafficking of membrane receptors. No drugs are known to directly target SNX3, nor is it currently considered a direct therapeutic target or clinical biomarker[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin-3 (SNX3).